首页> 外文期刊>BMC Genomics >Development of pathogenicity predictors specific for variants that do not comply with clinical guidelines for the use of computational evidence
【24h】

Development of pathogenicity predictors specific for variants that do not comply with clinical guidelines for the use of computational evidence

机译:针对不符合使用计算机证据的临床指导方针的变异的致病性预测因子的开发

获取原文
           

摘要

Background Strict guidelines delimit the use of computational information in the clinical setting, due to the still moderate accuracy of in silico tools. These guidelines indicate that several tools should always be used and that full coincidence between them is required if we want to consider their results as supporting evidence in medical decision processes. Application of this simple rule certainly decreases the error rate of in silico pathogenicity assignments. However, when predictors disagree this rule results in the rejection of potentially valuable information for a number of variants. In this work, we focus on these variants of the protein sequence and develop specific predictors to help improve the success rate of their annotation. Results We have used a set of 59,442 protein sequence variants (15,723 pathological and 43,719 neutral) from 228 proteins to identify those cases for which pathogenicity predictors disagree. We have repeated this process for all the possible combinations of five known methods (SIFT, PolyPhen-2, PON-P2, CADD and MutationTaster2). For each resulting subset we have trained a specific pathogenicity predictor. We find that these specific predictors are able to discriminate between neutral and pathogenic variants, with a success rate different from random. They tend to outperform the constitutive methods but this trend decreases as the performance of the constitutive predictor improves (e.g. with PON-P2 and PolyPhen-2). We also find that specific methods outperform standard consensus methods (Condel and CAROL). Conclusion Focusing development efforts on the case of variants for which known methods disagree we may obtain pathogenicity predictors with improved performances. Although we have not yet reached the success rate that allows the use of this computational evidence in a clinical setting, the simplicity of the approach indicates that more advanced methods may reach this goal in a close future.
机译:背景技术由于计算机工具的准确性仍然中等,因此严格的准则限制了在临床环境中使用计算信息。这些准则表明,应始终使用几种工具,并且如果我们想将其结果视为医疗决策过程中的支持证据,则需要它们之间完全一致。应用此简单规则肯定会降低计算机病原学分配的错误率。但是,当预测变量不同意时,此规则将导致许多变体的潜在有价值信息被拒绝。在这项工作中,我们专注于蛋白质序列的这些变异,并开发出特定的预测因子,以帮助提高其注释的成功率。结果我们使用了来自228种蛋白质的59,442种蛋白质序列变体(15,723种病理性和43,719种中性),以鉴定那些致病性预测指标不一致的病例。我们已对五种已知方法(SIFT,PolyPhen-2,PON-P2,CADD和MutationTaster2)的所有可能组合重复了此过程。对于每个结果子集,我们都训练了一个特定的致病性预测因子。我们发现这些特定的预测因子能够区分中性和致病性变异,成功率不同于随机。它们往往胜过本构方法,但是随着本构预测器性能的提高(例如,使用PON-P2和PolyPhen-2),这种趋势会降低。我们还发现,特定方法优于标准共识方法(Condel和CAROL)。结论将开发工作集中在已知方法不同的变体情况下,我们可以获得性能提高的致病性预测因子。尽管我们尚未达到允许在临床环境中使用此计算证据的成功率,但该方法的简单性表明,更先进的方法可能会在不久的将来达到这一目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号